Table 3.
Summary of selected ongoing clinical trials of PD-1/PD-L1 ICIs in NHL.
| Disease, phase | Phase | Intervention | ClinicalTrials.gov NCT reference |
|---|---|---|---|
| Aggressive B-cell lymphomas | |||
| DLBCL, r/r | Ib | Pembrolizumab in combination with tisagenlecleucel | NCT03630159 |
| DLBCL and PMBCL, r/r | II | Pembrolizumab in combination with copanlisib | NCT03484819 |
| DLBCL with PD-L1 genetic alterations, r/r | II | Pembrolizumab monotherapy | NCT03990961 |
| Aggressive B-cell lymphoma, untreated | II | Nivolumab in combination with DA-EPOCH-R | NCT03749018 |
| HGBCL with MYC, BCL2, and/or BCL6 rearrangement, untreated | II | Nivolumab as consolidation after DA-EPOCH-R | NCT03620578 |
| DLBCL, untreated | II | Avelumab as induction and maintenance with R-CHOP | NCT03244176 |
| EBV-positive NHL and EBV-positive PTLD, untreated or relapsed | II | Nivolumab monotherapy | NCT03258567 |
| DLBCL, r/r | Ib | Magrolimab (Hu5F9-G4) in combination with rituximab or R-GemOx | NCT02953509 |
| Aggressive B-cell lymphomas, extranodal | |||
| PCNSL or PTL, r/r | II | Nivolumab monotherapy | NCT02857426 |
| CNS lymphoma, r/r | II | Nivolumab in combination with ibrutinib | NCT03770416 |
| PCNSL, relapse after prior 1st line HiDMTX | II | Pembrolizumab monotherapy | NCT02779101 |
| PCNSL, r/r | I | Nivolumab in combination with pomalidomide | NCT03798314 |
| Transformed indolent B-cell lymphoproliferative diseases | |||
| RT-DLBCL or transformed FL | I | Nivolumab in combination with copanlisib | NCT03884998 |
| RT-DLBCL | II | Atezolizumab in combination with obinutuzumab+venetoclax | NCT04082897 |
| Peripheral T-cell lymphomas | |||
| NKTL, untreated or r/r | I | Nivolumab in combination with L-asparaginase/GDP | NCT04230330 |
| NKTCL, untreated | II | Sintilimab in combination with Peg-asparaginase/GemOx | NCT04127227 |
| MF and SS, r/r | Pembrolizumab combined with radiotherapy | NCT03385226 | |
| ALCL, r/r | II | Nivolumab as treatment or consolidative immunotherapy | NCT03703050 |
| Cutaneous TCL, r/r | II | Atezolizumab monotherapy | NCT03357224 |
| PTCL or cutaneous TCL, r/r | I/II | Durvalumab±lenalidomide | NCT03011814 |
Abbreviations: ALCL: anaplastic large cell lymphoma; CNS: central nervous system; DLBCL: diffuse large B-cell lymphoma; EBV: Epstein-Bar virus; FL: follicular lymphoma; HGBCL: high-grade B-cell lymphoma; HiDMTX: high-dose methotrexate; LPD: lymphoproliferative disorders; NHL: non-Hodgkin lymphoma; NKTL: natural killer T-cell lymphoma; PCNSL: primary central nervous system lymphoma; PD-1: programmed cell-death protein 1; PD-L1: programmed cell-death 1 ligand; PMBCL: primary mediastinal B-cell lymphoma; PTCL: peripheral T-cell lymphoma; PTL: primary testicular lymphoma; RT-DLBCL: Richter's transformation of CLL to DLBCL; TCL: T-cell lymphoma.